Optimal control of treatment in a mathematical model of chronic myelogenous leukemia.
We consider a mathematical model of drug therapy for chronic myelogenous leukemia for an individual patient over a fixed time horizon. The disease dynamics are given by a system of ordinary differential equations that describe the interaction between naive T cells, effector T cells and leukemic cancer cells in a hypothetical patient. We introduce two drug therapies into this model, one a targeted therapy, and the other a broad cytotoxic therapy. Our goal is to find treatment regimens that minimize the cancer cell count and the deleterious effects of the drugs for a given patient. We examine the control setting analytically, and include numerical solutions to illustrate the optimal regimens under various assumptions.
Nanda
Seema
S
Tata Institute of Fundamental Research, IISc Campus, P.B. 1234, Bangalore 560012, India. nanda@math.tifrbng.res.in
Moore
Helen
H
Lenhart
Suzanne
S
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D003561:Cytarabine / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008433:Mathematics; D008954:Models, Biological; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D003561:Cytarabine; D000068877:Imatinib Mesylate